Home β€Ί Healthcare β€Ί Vaccines β€Ί Healthcare Contract Manufacturing Outsourcing (CMO) Market

Healthcare Contract Manufacturing Outsourcing (CMO) Market - Strategic Insights and Forecasts (2025-2030)

πŸ“₯ Download Free SampleπŸ’¬ Speak to Analyst
$3,950
Single User License
Access Full Insights
Report OverviewSegmentationTable of ContentsCustomize Report

Table of Contents

1. Introduction

1.1. Market Overview

1.2. COVID-19 Scenario

1.3. Market Definition

1.4. Market Segmentation

2. Research Methodology

2.1. Research Data

2.2. Assumptions

3. Executive Summary

3.1. Research Highlights

4. Market Dynamics

4.1. Market Drivers

4.2. Market Restraints

4.3. Porters Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. Healthcare Contract Manufacturing Outsourcing Market Analysis, by Services

5.1. Introduction

5.2. Pharmaceutical CMO

5.2.1. Active Pharmaceutical Ingredients (API) Manufacturing

5.2.2. Final Dose Formulation (FDF) Manufacturing

5.2.2.1. Injectable Dose Formulations

5.2.2.2. Solid Dose Formulations

5.2.2.3. Semi-solid Dose Formulations

5.2.2.4. Liquid Dose Formulations

5.2.3. Packaging

5.3. Medical Device CMO

5.3.1. Design Outsourcing

5.3.2. Device Manufacturing

5.3.3. Final Goods Assembly

6. Healthcare Contract Manufacturing Outsourcing Market Analysis, by Type

6.1. Introduction

6.2. Sterile

6.3. Non-sterile

7. Healthcare Contract Manufacturing Outsourcing Market Analysis, by Geography

7.1. Introduction

7.2. North America

7.2.1. United States

7.2.2. Canada

7.2.3. Mexico

7.3. South America

7.3.1. Brazil

7.3.2. Argentina

7.3.3. Others

7.4. Europe

7.4.1. UK

7.4.2. Germany

7.4.3. France

7.4.4. Italy

7.4.5. Others

7.5. Middle East and Africa

7.5.1. Saudi Arabia

7.5.2. United Arab Emirates

7.5.3. Israel

7.5.4. Others

7.6. Asia Pacific

7.6.1. Japan

7.6.2. China

7.6.3. India

7.6.4. South Korea

7.6.5. Taiwan

7.6.6. Thailand

7.6.7. Indonesia

7.6.8. Others

8. Competitive Environment and Analysis

8.1. Major Players and Strategy Analysis

8.2. Emerging Players and Market Lucrativeness

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Vendor Competitiveness Matrix

9. Company Profiles

9.1. Jubilant Pharma Limited

9.2. Pfizer Inc.

9.3. Lonza Group

9.4. AGC Biologics

9.5. Recipharm AB

9.6. Catalent, Inc.

9.7. The Aenova Group

9.8. Baxter

9.9. Boehringer Ingelheim International GmbH

9.10. DPx Holdings

List of Figures

List of Tables

REPORT DETAILS

Report ID:KSI061610053
Published:Feb 2026
Pages:145
Format:PDF, Excel, PPT, Dashboard
πŸ“₯ Download SampleπŸ“ž Speak to AnalystπŸ“§ Request Customization

Need Assistance?

Our research team is available to answer your questions.

Contact Us